Transcriptomics

Dataset Information

117

Mucosal expression profiling in patients with inflammatory bowel disease before and after first infliximab treatment


ABSTRACT: We used microarrays to identify mucosal gene signatures predictive of response to infliximab (IFX) in patients with inflammatory bowel disease (IBD) and to gain more insight into the pathogenesis of IBD. Keywords: drug response and treatment effect Mucosal biopsies were obtained at endoscopy in actively inflamed mucosa from 61 IBD patients (24 ulcerative colitis (UC), 19 Crohn’s colitis (CDc) and 18 Crohn’s ileitis (CDi)), refractory to corticosteroids and/or immunosuppression, before and 4-6 weeks after (except for 1 CDc patient) their first infliximab infusion and in normal mucosa from 12 control patients (6 colon and 6 ileum). The patients were classified for response to infliximab based on endoscopic and histologic findings at 4-6 weeks after first infliximab treatment. Total RNA was isolated from intestinal mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

REANALYSED by: E-GEOD-16879

ORGANISM(S): Homo sapiens  

SUBMITTER: Frans Schuit   Gert De Hertogh  Karel Geboes  Paul Rutgeerts  Leentje Van Lommel  Ingrid Arijs  Kristel Van Steen 

PROVIDER: E-GEOD-16879 | ArrayExpress | 2009-11-02

SECONDARY ACCESSION(S): GSE16879PRJNA117589

REPOSITORIES: GEO, ArrayExpress

Dataset's files

Source:
Action DRS
E-GEOD-16879.idf.txt Idf
E-GEOD-16879.processed.1.zip Processed
E-GEOD-16879.raw.1.zip Raw
E-GEOD-16879.raw.2.zip Raw
E-GEOD-16879.raw.3.zip Raw
Items per page:
1 - 5 of 7
altmetric image

Publications

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

Arijs Ingrid I   De Hertogh Gert G   Lemaire Katleen K   Quintens Roel R   Van Lommel Leentje L   Van Steen Kristel K   Leemans Peter P   Cleynen Isabelle I   Van Assche Gert G   Vermeire Séverine S   Geboes Karel K   Schuit Frans F   Rutgeerts Paul P  

PloS one 20091124 11


<h4>Background</h4>Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect. We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD.<h4>Methodology/principal findings</h4>Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4-6 weeks after their f  ...[more]

Similar Datasets

2009-11-03 | GSE16879 | GEO
2015-07-28 | E-GEOD-16879 | ExpressionAtlas
2016-01-01 | S-EPMC5046040 | BioStudies
2018-01-01 | S-EPMC6305625 | BioStudies
2015-01-01 | S-EPMC4625751 | BioStudies
2010-01-06 | E-GEOD-14580 | ArrayExpress
1000-01-01 | S-EPMC5048766 | BioStudies
2019-01-01 | S-EPMC6893280 | BioStudies
2009-01-01 | S-EPMC2776509 | BioStudies
2014-12-22 | E-GEOD-51785 | ArrayExpress